Fideuram Intesa Sanpaolo Private Banking S.P.A. Purchases New Position in Neurocrine Biosciences, Inc. $NBIX

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 13,154 shares of the company’s stock, valued at approximately $1,866,000.

Other large investors also recently bought and sold shares of the company. USA Financial Formulas purchased a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Golden State Wealth Management LLC increased its stake in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $49,000. Finally, Leonteq Securities AG purchased a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $58,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 3,810 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total transaction of $590,588.10. Following the transaction, the director directly owned 2,429 shares in the company, valued at $376,519.29. The trade was a 61.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the transaction, the director owned 511,293 shares in the company, valued at approximately $78,907,848.69. This represents a 32.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 263,898 shares of company stock worth $40,779,769 in the last ninety days. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Truist Financial boosted their price objective on Neurocrine Biosciences from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wells Fargo & Company cut their price objective on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Sanford C. Bernstein assumed coverage on Neurocrine Biosciences in a research note on Friday. They set an “outperform” rating and a $221.00 price objective for the company. Finally, HC Wainwright boosted their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $185.90.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $156.70 on Friday. The stock has a market cap of $15.76 billion, a P/E ratio of 24.14, a P/E/G ratio of 1.18 and a beta of 0.34. The stock’s 50 day simple moving average is $136.68 and its 200-day simple moving average is $138.90. Neurocrine Biosciences, Inc. has a 1-year low of $117.59 and a 1-year high of $162.39.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.